| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 1261 |
PLGA(75:25)MW:50K,聚乳酸-羟基乙酸共聚物,化学结构 |
245 |
axc |
2026-01-09 |
| 1262 |
PEG修饰碳酸钠改性后的中空二氧化锰包载地高辛和乳酸氧化酶,100-150nm |
211 |
axc |
2026-01-09 |
| 1263 |
PCL2K-PEG2K-Mal,聚己内酯-聚乙二醇-马来酰基嵌段共聚物的反应条件 |
137 |
axc |
2026-01-09 |
| 1264 |
PCL2K-PEG2K,聚己内酯-聚乙二醇嵌段共聚物,实验用途 |
115 |
axc |
2026-01-09 |
| 1265 |
PAE10K-PEG5K,聚酰胺胺-聚乙二醇共聚物的溶解度 |
122 |
axc |
2026-01-09 |
| 1266 |
Rhodamine X amine,ROX NH2,罗丹明 X-氨基 |
153 |
HLL |
2026-01-09 |
| 1267 |
NOTA-PSMA,1,4,7-三氮杂环壬烷三乙酸-前列腺特异性膜抗原抑制剂 |
144 |
HLL |
2026-01-09 |
| 1268 |
HYNIC-PSMA,肼基烟酰胺-前列腺特异性膜抗原抑制剂 |
135 |
HLL |
2026-01-09 |
| 1269 |
PSMA1007,前列腺特异性膜抗原抑制剂 1007 |
131 |
HLL |
2026-01-09 |
| 1270 |
tert-Butyl-DCL-hexyl-NHS ester,叔丁基-2-((4-氨基甲酰基苯基)氨基)-2-氧代乙酸-己基-活性酯 |
144 |
HLL |
2026-01-09 |
| 1271 |
DCL(PSMA inhibitor)(ACUPA),2-((4-氨基甲酰基苯基)氨基)-2-氧代乙酸(前列腺特异性膜抗原抑制剂) |
119 |
HLL |
2026-01-09 |
| 1272 |
NOTA-P2-RM26,1,4,7-三氮杂环壬烷三乙酸-P2-RM26 肽 |
154 |
HLL |
2026-01-09 |
| 1273 |
(68Ga)Nota-PRGD2,镓 [68Ga] 标记的 1,4,7-三氮杂环壬烷三乙酸-脯氨酸-精氨酸-甘氨酸-天冬氨酸-天冬氨酸 |
163 |
HLL |
2026-01-09 |
| 1274 |
NOTA-WL12,1,4,7-三氮杂环壬烷三乙酸-WL12 肽 |
133 |
HLL |
2026-01-09 |
| 1275 |
Azido cyclic(RGDyK),叠氮基环肽(精氨酸-甘氨酸-天冬氨酸-酪氨酸-赖氨酸) |
120 |
HLL |
2026-01-09 |
| 1276 |
X-Rhodamine maleimide,X-罗丹明-马来酰亚胺 |
126 |
HLL |
2026-01-09 |
| 1277 |
Texas Red amine,德克萨斯红-氨基 |
125 |
HLL |
2026-01-09 |
| 1278 |
Texas Red-X NHS ester,mixed isomers,德克萨斯红-X-活性酯(混合异构体) |
126 |
HLL |
2026-01-09 |
| 1279 |
Texas Red maleimide,德克萨斯红-马来酰亚胺 |
157 |
HLL |
2026-01-09 |
| 1280 |
474424-15-2,DOTA-PNP,1,4,7,10-四氮杂环十二烷四乙酸-对硝基苯酯 |
146 |
HLL |
2026-01-09 |
| 1281 |
HBED-CC-tris(tBu)ester,N,N'-二(2-羟基苄基)乙二胺-N,N'-二乙酸-环己基酯三叔丁酯 |
118 |
HLL |
2026-01-09 |
| 1282 |
4-Formyl-N,N,N-trimethylanilinium,4-甲酰基-N,N,N-三甲基苯胺鎓 |
98 |
HLL |
2026-01-09 |
| 1283 |
Succinimidyl-Hynic hydrochloride,琥珀酰亚胺基-肼基烟酰胺盐酸盐 |
135 |
HLL |
2026-01-09 |
| 1284 |
MeTz-PEG11-NOTA,甲基四嗪-十一聚乙二醇-1,4,7-三氮杂环壬烷三乙酸 |
106 |
HLL |
2026-01-09 |
| 1285 |
MeTz-PEG7-NOTA,甲基四嗪-七聚乙二醇-1,4,7-三氮杂环壬烷三乙酸 |
137 |
HLL |
2026-01-09 |
| 1286 |
NH2-PEG2K-SH,氨基-聚乙二醇-巯基的合成步骤 |
160 |
axc |
2026-01-09 |
| 1287 |
mPEG-COOH,MW:5000,羧基末端聚乙二醇的合成路线 |
159 |
axc |
2026-01-09 |
| 1288 |
MA-NHS,CAS:38862-25-8,马来酰亚胺-N-羟基琥珀酰亚胺 |
127 |
axc |
2026-01-09 |
| 1289 |
Mal-PEG1K-NHS,马来酰基-聚乙二醇1k-氮羧酸酯的物理化学特性 |
125 |
axc |
2026-01-09 |
| 1290 |
99%纯纳米级石墨烯纳米片1-10nm,CAS:7440-44-0,99% Purity Few-Layer Graphene Nanoplatelets |
146 |
YFF |
2026-01-09 |
| 1291 |
[Ce(H2O)3(H2PXBP)]二维材料,[Ce(H₂O)₃(H₂PXBP)] Two-Dimensional Material的结构特征 |
172 |
YFF |
2026-01-09 |
| 1292 |
(CoMnFeZnCu)3O4 HEO,钴锰铁锌铜高熵氧化物的合成方法 |
164 |
YFF |
2026-01-09 |
| 1293 |
PLGA-Pullulan的物理化学特性 |
188 |
kx |
2026-01-08 |
| 1294 |
DSPE-hyd-PEG-Acrylate,二硬脂酰基磷脂酰乙醇胺-腙键-聚乙二醇-丙烯酸酯的合成方法 |
140 |
wyh |
2026-01-08 |
| 1295 |
Cholesterol-PEG-Indocyanine Green;胆固醇-聚乙二醇-吲哚菁绿的合成方法 |
110 |
wyh |
2026-01-08 |
| 1296 |
4-Azido-L-phenylalanine,4-氮杂-L-苯丙氨酸的应用特征 |
160 |
whl |
2026-01-08 |
| 1297 |
CAS: 33173-53-4,UV-Tracer DBCO NHS Ester |
103 |
whl |
2026-01-08 |
| 1298 |
Stearic acid-PEG-Phenylboronic acid,硬脂酸-聚乙二醇-苯硼酸的应用场景与优势 |
149 |
wyh |
2026-01-08 |
| 1299 |
DMG-PEG2k-BSA,1,2-二肉豆蔻酸甘油酯-聚乙二醇2k-牛血清白蛋白的应用场景与优势 |
113 |
wyh |
2026-01-08 |
| 1300 |
GAS-PEG-GAS,聚乙二醇二酰胺琥珀酰亚胺戊二酸酯的合成工艺优化 |
98 |
wyh |
2026-01-08 |
| 1301 |
Mannose-PEG-Rhodamine,甘露糖-聚乙二醇-罗丹明的分子结构与功能模块 |
134 |
wyh |
2026-01-08 |
| 1302 |
Cyanine7-PEG-Thiol,近红外荧光染料-聚乙二醇-巯基的生物医学应用场景 |
118 |
wyh |
2026-01-08 |
| 1303 |
Maleimide-PEG-Cholic Acid的应用场景与功能集成 |
92 |
wyh |
2026-01-08 |
| 1304 |
SPA-PEG-SPA,聚乙二醇二琥珀酰亚胺丙酸酯的纯化与表征 |
105 |
wyh |
2026-01-08 |
| 1305 |
FITC-乳酸,FITC–Lactic acid,异硫氰酸荧光素–乳酸的组成特点 |
150 |
axc |
2026-01-08 |